MedTrace Logo

Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)

NCT01797419 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2013-10-28

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of GS-5806 in hospitalized infants with RSV.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

DRUG

GS-5806

Single dose, oral liquid, .5 mL/kg

DRUG

Placebo

Single dose, oral liquid, .5 mL/kg

Sponsors & Collaborators

Principal Investigators

  • Peter Sly, MD · Queensland Children's Medical Research Unit, Herston, AUS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
1 Hour
Max Age
24 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01797419 on ClinicalTrials.gov